Ann: Shareholder Update , page-18

SoT,

So we should expect a license from Roche, Pfizer and/or Janssen this year?? Or at least Pfizer or Janssen, since they are "close"? Is that the info you get from Mgmt and were able to confirm with major shareholders?

I am all for "evolving/optimizing/improving" the libraries/discovery platform. When does that translate into a sustainable business plan? Q4? Next year? or is that not so important?


Also, not to be critical, but they are not identifying "cell-specific peptides that can penetrate cell membranes" as you wrote, they are identifying peptides that bind to cell-specific receptors and carry a cargo into cells because these receptors recycle into cells from the membrane. They believe they have a better way to release these cargos from this recycling (endosomal/vesicle pathway) process into the cytoplasm where most of the targets exist. That is the basic concept for their screening method. And the concept is not new.